Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx (Nasdaq: MDXG) launched AMNIOFIX Thyroid Shields, a DHACM allograft line for endocrine surgery designed to protect the recurrent laryngeal nerve and parathyroid glands after thyroidectomy.
The product is preconfigured for operating-room use, shelf-stable up to five years, manufactured with the PURION process, and supported by a retrospective single-center study showing a 76% reduction in 24-hour RLN damage (3.4% vs 14.4%, p<0.01).
MIMEDX (Nasdaq: MDXG) reported record 2025 results with Q4 net sales $118M (+27% YoY) and full-year net sales $419M (+20% YoY). Q4 GAAP net income was $15M and full-year net income was $49M. Adjusted EBITDA for Q4 was $29M (25% of net sales). Cash totaled $166M at year-end. The board authorized a $100M share repurchase over two years. For 2026 the company estimates net sales of $340–360M and adjusted EBITDA margin in the mid-to-high teens.
MiMedx (Nasdaq: MDXG) will report fourth quarter and full year 2025 operating and financial results after market close on Wednesday, February 25, 2026.
The senior management team will host a webcast and conference call beginning at 4:30 p.m. ET on February 25. A replay will be available on the company website for approximately 30 days.
MIMEDX (Nasdaq: MDXG) entered an exclusive distribution agreement with Summit Products Group on February 4, 2026 to add three 510(k) cleared surgical and wound-care products: Hydrelix, NovaForm, and G4Derm Plus.
The products include a soluble bovine collagen powder, a bioglass-collagen wound matrix, and a flowable peptide matrix designed to support wound healing and manage bioburden.
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.
The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.
Summary not available.
MiMedx (Nasdaq: MDXG) entered an exclusive U.S. distribution agreement with Regen Lab USA to distribute RegenKit®-Wound Gel, an autologous PRP and autologous thrombin serum wound gel, on Dec 22, 2025. The product concentrates growth factors, platelets, plasma proteins and nutrients in a fibrin scaffold and removes iron-laden red blood cells.
RegenKit was approved by FDA in 2022 and is covered nationally by CMS/LCD for diabetic chronic wounds under HCPCS code G0465. MiMedx says the kit adds a differentiated autologous option to its Advanced Wound Care portfolio and that upcoming LCD implementation on Jan 1, 2026 strengthens its competitive position.
MiMedx (NASDAQ: MDXG) announced a peer-reviewed publication on Dec 19, 2025 in the Journal of Inflammation reporting in vitro findings for Purion processed dehydrated (DHACM) and lyophilized (LHACM) human amnion chorion membrane allografts.
The study found that DHACM and LHACM exhibit multifactorial immunomodulatory effects on inflammatory monocytes and macrophages and enhance pro-reparative functions including efferocytosis and cell survival, suggesting potential to help reset the wound-healing cascade in complex wounds characterized by persistent inflammation.
MiMedx (Nasdaq: MDXG) reported interim results from the CAMPAIGN randomized controlled trial evaluating EPIEFFECT versus standard of care (SOC) for nonhealing diabetic foot ulcers. The interim analysis (71 patients) showed a posterior probability of superiority of 98.5% against a 90% success threshold. Results were published in the International Journal of Tissue Repair and an expanded 88-patient sample was presented at TRES on Oct 30, 2025. Enrollment is ongoing and MiMedx highlighted potential relevance for pending Medicare and commercial LCD implementations effective Jan 1, 2026.
MiMedx (Nasdaq: MDXG) announced that senior management will participate in two investor conferences in New York in November 2025.
Key details: Craig-Hallum 16th Annual Alpha Select Conference in New York on Tuesday, November 18, 2025 with 1:1 sessions, and Canaccord MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 20, 2025 with 1:1 sessions. Investors seeking meetings should contact their Craig-Hallum or Canaccord representative.